| Advanced and Metastatic Breast Cancer |
1 |
1 |
| Brain Metastasis |
0 |
0.95 |
| Brain |
0 |
0.75 |
| Brain Tumor |
0 |
0.63 |
| Breast Cancer |
0 |
0.62 |
| Metastasis |
0 |
0.53 |
| Biologic Therapy |
0 |
0.51 |
| Estrogen Receptor-Positive (ER+) Breast Cancer |
0 |
0.34 |
| Genomic Medicine |
0 |
0.25 |
| Triple Negative Breast Cancer |
0 |
0.25 |
| Antineoplastic Drug |
0 |
0.22 |
| Toxicology |
0 |
0.22 |
| Breast |
0 |
0.21 |
| Cancer |
0 |
0.21 |
| Targeted Cancer Therapy |
0 |
0.17 |
| Tumor |
0 |
0.13 |
| Receptors |
0 |
0.12 |
| Blood |
0 |
0.1 |
| Central Nervous System |
0 |
0.1 |
| Care and Maintenance of Vision |
0 |
0.09 |
| Epidermal Growth Factor Receptor |
0 |
0.09 |
| Estrogen |
0 |
0.08 |
| Humanized Monoclonal Antibody |
0 |
0.07 |
| Radiation Therapy |
0 |
0.07 |
| Radiosurgery |
0 |
0.07 |
| Cataract |
0 |
0.05 |
| Chemotherapy |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |
| Tyrosine Kinase Inhibitor |
0 |
0.04 |
| Biopsy |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Preventive Screening |
0 |
0.03 |
| Surgery |
0 |
0.03 |
| Tyrosine Kinase |
0 |
0.03 |
| Headache |
0 |
0.02 |
| Patient Safety |
0 |
0.02 |
| A-Scan Biometry |
0 |
0.01 |
| Adverse Effects |
0 |
0.01 |
| Aromatase Inhibitors |
0 |
0.01 |
| Brachial |
0 |
0.01 |
| Cerebrospinal Fluid |
0 |
0.01 |
| Dizziness |
0 |
0.01 |
| Hematology |
0 |
0.01 |
| Immunotherapy |
0 |
0.01 |
| Magnetic Resonance Imaging |
0 |
0.01 |
| mTOR Inhibitor |
0 |
0.01 |
| Neoadjuvant Therapy |
0 |
0.01 |
| Platinum |
0 |
0.01 |
| Prognosis |
0 |
0.01 |
| Scan |
0 |
0.01 |
| Tissue |
0 |
0.01 |
| Weakness |
0 |
0.01 |